Financial Statement and Notes to the Financial Statements CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME For the Year Ended 30 June 2014 This statement should be read in conjunction with the notes to the financial statements. Note 2014 2013 $ $ Continuing Operations Revenue 2 597,940 639,849 Other income  2  775,833  824,333 1,373,773 1,464,182 Royalties & licence fees  (192,753)  (30,000) Research and development  (3,757,869)  (1,280,012) Employment related  (2,444,015)  (1,832,065) Share based expense  (355,116)  (518,749) Impairment costs  -  (1,503,296) Travel related costs  (585,359)  (345,826) Consultants costs  (652,839)  (336,570) Occupancy costs  (121,582)  (100,153) Corporate expenses  (646,315)  (531,686) Foreign exchange translation  (111,399)  1,526,215 (8,867,247) (4,952,142) Loss before income tax (7,493,474)  (3,487,960)  Income tax benefit  4  454,365  - Loss for the year attributable to members of the parent entity  (7,039,109)  (3,487,960) Other Comprehensive Income  Items that may be reclassified subsequently to profit and loss Other Comprehensive Income for the year, Foreign exchange translation, net of tax  7,747  (1,313,792) Total Comprehensive Income for the year  (7,031,362)  (4,801,752) Total Comprehensive Income attributable to members of the parent entity (7,031,362)  (4,801,752) Earnings per share (cents per share) Basic and diluted for loss for the year attributable to ordinary equity holders of the parent entity  Cents per share, with the comparative adjusted for the share consolidation at 25:1 in July 2013  6  (7.81)  (8.25) Benitec Biopharma Ltd  Annual Report 2014 Page 19